A5101703751- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Colorectal Cancer Screening and Detection
- Synthesis and Biological Evaluation
- HIV/AIDS drug development and treatment
- Allergic Rhinitis and Sensitization
- HIV-related health complications and treatments
- HIV/AIDS Research and Interventions
- Peptidase Inhibition and Analysis
- Asthma and respiratory diseases
- Cancer therapeutics and mechanisms
- Congenital Heart Disease Studies
- Neonatal Respiratory Health Research
- Mycobacterium research and diagnosis
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Research
- Hepatitis C virus research
- Hormonal and reproductive studies
- Radiomics and Machine Learning in Medical Imaging
- Ubiquitin and proteasome pathways
- Sexual function and dysfunction studies
- Diabetes and associated disorders
- Retinoids in leukemia and cellular processes
- HIV Research and Treatment
Gilead Sciences (United States)
2025
Providence College
2020-2024
Centro de Investigación del Cáncer
2024
Universidade de São Paulo
2024
GlaxoSmithKline (United States)
2020-2024
Soochow University
2024
Universidade da Região de Joinville
2024
Instituto do Câncer do Estado de São Paulo
2024
North Kansas City Hospital
2021
Nottingham City Council
2017-2019
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent combination standard-care therapies.
439572 Background: Belamaf, a BCMA-targeted antibody drug conjugate, has previously demonstrated clinical activity and manageable safety profile, supporting its use in combination with standard-of-care (SoC) therapies RRMM. DREAMM-7 (NCT04246047) is global, randomized, open-label, phase III head-to-head trial evaluating the efficacy of BVd triplet vs SoC triplet, DVd, patients (pts) RRMM ≥1 prior line therapy (LOT). Methods: Pts LOT were randomized (1:1) to BVd: B 2.5 mg/kg IV Q3W + V 1.3...
New national guidance on urgent referral for investigation of colorectal cancer included faecal occult blood testing in 2015. A service evaluation immunochemical (FIT) and anaemia as risk stratification tools symptomatic patients suspected having CRC was undertaken. Postal FIT incorporated into the 2-week wait (2WW) pathway all without rectal bleeding 2016. Patients were investigated 2WW normal, outcomes investigations recorded prospectively. Anaemia defined a haemoglobin level below 120 g/l...
8502 Background: Belantamab mafodotin, a B-cell maturation antigen targeting immunoconjugate, demonstrated clinically meaningful, single-agent activity in patients with heavily pre-treated RRMM refractory to an immunomodulatory agent, proteasome inhibitor, and and/or intolerant anti-CD38 monoclonal antibody (DREAMM-2, NCT03525678, Lancet Oncol.2020). The multimodal mechanism of action manageable safety profile make belantamab mafodotin promising candidate for use different combination...
Abstract Background Black communities are disproportionately affected by HIV and may have a greater lifetime risk of comorbidities compared with non-Black people (PWH). Despite this, they historically been underrepresented in clinical studies. Here, we report efficacy safety through 5 years first-line therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) PWH. Methods Studies 1489 (NCT02607930; B/F/TAF vs dolutegravir/abacavir/lamivudine [DTG/ABC/3TC]) 1490 (NCT02607956;...
Black and Hispanic/Latine people are disproportionately affected by HIV-1 may have a greater risk of comorbidities than non-Black non-Hispanic/Latine with HIV. However, they historically been underrepresented in HIV clinical studies. We aimed to assess the efficacy safety first-line antiretroviral therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) over 5 years present two post hoc pooled analyses participants who received B/F/TAF up week 240 studies 1489 (NCT02607930) 1490...
Inpatient diabetes management involves frequent assessment of glucose levels for treatment decisions. Here we describe a program inpatient real-time continuous monitoring (rtCGM) at community hospital and the accuracy rtCGM-based estimates.Adult inpatients with preexisting managed intensive insulin therapy diagnosis coronavirus disease 2019 (COVID-19) were monitored via rtCGM safety. An system transmitted concentration trending information 5-minute intervals to nearby smartphones, which...
8017 Background: Belantamab mafodotin (belamaf; BLENREP) is a B-cell maturation antigen-targeting antibody–drug conjugate approved for patients (pts) with RRMM as monotherapy at 2.5 mg/kg Q3W. Preclinical data demonstrate synergy between belamaf and lenalidomide (Len), suggesting added benefit when combined standard of care such Len + dexamethasone (Dex). DREAMM-6 (NCT03544281) Arm A evaluating in combination LenDex pts RRMM. Methods: This ongoing, two-part, two-arm, open-label study...
Approximately 70% of veterans with hepatitis C virus infection have at least one psychiatric illness. The advent direct-acting antiviral (DAA) therapy provided an alternative to interferon-alpha regimens and revolutionized treatment, however, the extent effects attributed these agents are unclear. primary objective this pilot study was prospectively analyze outcomes, specifically depression, in who initiated on DAA therapy.In single center, prospective cohort study, outcomes were analyzed...
<h3>Introduction</h3> Latest NICE guidance (NG12) on criteria warranting urgent referral for investigation colorectal cancer (CRC) includes the use of faecal occult blood testing. We present an interim analysis 'Getting FIT' project – a service evaluation immunochemical testing (FIT) in symptomatic patients suspected having CRC. <h3>Method</h3> In September 2016 we incorporated FIT into our Straight to test (STT) pathway with support local commissioners. GPs were given access eligible low...
Introduction NICE guidance (NG12) published in 2015, on indications for urgent referral possible colorectal cancer (CRC) included the use of faecal occult blood tests (FOB) but did not specify type FOB to be used. Quantitative immunochemical (FIT) are now available analysis blood. Recent draft recommendations from propose using a FIT with 10 µg Hb/g faeces threshold guide primary care although it is unclear if all analysers perform same way clinical setting. Method In September 2016 was...